Fortress Biotech(US:FBIO) ZACKS·2024-08-13 22:15分组1 - Fortress Biotech reported a quarterly loss of $0.73 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.32, and an improvement from a loss of $3.60 per share a year ago, resulting in an earnings surprise of 44.70% [1] - The company posted revenues of $14.9 million for the quarter ended June 2024, which was below the Zacks Consensus Estimate by 0.49% and a decrease from $17.39 million in the same quarter last year [2] - Fortress Biotech shares have declined approximately 41.2% year-to-date, contrasting with the S&P 500's gain of 12.1% [3] 分组2 - The earnings outlook for Fortress Biotech is mixed, with the current consensus EPS estimate for the upcoming quarter at -$1.36 on revenues of $28.21 million, and for the current fiscal year at -$5.07 on revenues of $81.22 million [7] - The Medical - Biomedical and Genetics industry, to which Fortress Biotech belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]